Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence

Abstract excerpt

Melanoma is a disease characterized by lesions that activate ERK. Although 70% of cutaneous melanomas harbor activating mutations in the BRAF and NRAS genes, the alterations that drive tumor progression in the remaining 30% are largely undefined. Vemurafenib, a selective inhibitor of RAF kinases, has clinical utility restricted to BRAF-mutant tumors. MEK inhibitors, which have shown clinical activity in...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cellular Mechanics and Interactions
• Share to Cutaneous Melanoma Detection and Management
• Share to Melanoma and MAPK Pathways